Citizen Petition On Phenylephrine Requests Pulling OTC Status For Children
This article was originally published in The Tan Sheet
Executive Summary
A citizen petition asks FDA to withdraw OTC approval for phenylephrine use by children under 12 years old and to raise the maximum dose to 25 mg, but also recommends more research to determine the most effective dosage level
You may also be interested in...
US OTC Oral Phenylephrine GRASE Meeting Stretched To Two Days In Rescheduled NDAC
Nonprescription Drugs Advisory Committee will meet online 11-12 September to consider data regarding generally recognized as safe and effective status for oral phenylephrine as a nasal decongestant which have become available since FDA last examined ingredient.
Asking Advisors About Phenylephrine Efficacy May Portend FDA Taking Streamlined Monograph Steps
NDAC will discuss whether data supports oral phenylephrine’s GRASE as nasal decongestant. Potential for removing phenylephrine from monograph could be linked to restricting nonprescription pseudoephedrine drugs to behind-the-counter sales since 2006 and overhaul of FDA monograph program authorized in 2020.
Petition Answers FDA Questions On Oral Phenylephrine Efficacy, Suggests Removal From Monograph
A citizen petition says studies have answered the question FDA and advisory committee members asked in 2007, for studies on the most effective dose of PE as a nasal decongestant. The studies show “PE is no more effective than placebo,” the petition says.